Skip to content
Subscriber Only

Amgen Plea Deal Over Misbranding Aranesp Awaits Approval

Amgen Inc., the world’s largest biotechnology company, agreed to pay $762 million in criminal penalties and civil settlements as it pleaded guilty to misbranding its anemia drug Aranesp.

The company, based in Thousand Oaks, California, entered a guilty plea yesterday to one misdemeanor charge before U.S. District Judge Sterling Johnson in Brooklyn, New York. Johnson said he will decide today whether to accept the firm’s deal with the government.